Skip to main content
Clinical Trials/NCT06727370
NCT06727370
Recruiting
Not Applicable

Cognitive Screening in Lung Cancer Patients

European Institute of Oncology1 site in 1 country200 target enrollmentJanuary 10, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Disease
Sponsor
European Institute of Oncology
Enrollment
200
Locations
1
Primary Endpoint
cognitive impairment
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Registry
clinicaltrials.gov
Start Date
January 10, 2024
End Date
December 31, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
European Institute of Oncology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
  • Age ≥ 18 years
  • Patients able to speak and read the local language(s) fluently
  • Acceptance and signature of informed consent

Exclusion Criteria

  • Presence of brain metastases
  • Patients with concomitant neurological or psychiatric disorders.
  • Patients undergoing brain radiotherapy
  • Previous diagnosis of lung cancer

Outcomes

Primary Outcomes

cognitive impairment

Time Frame: From baseline to 12 months

It will be the presence of cognitive impairment through the administration of a comprehensive neuropsychological assessment.Patient will complete cognitive evaluation which includes:the Montreal Cognitive Assessment and the Mini-Mental State Examination to assess global cognitive functioning;the Frontal Assessment Battery,the Stroop test color and word test ,and the Verbal Fluency Test for the evaluation of executive function;the Ray Auditory Verbal Learning Test for learning and memory;the forward and backward Digit Span and the Corsi Block-tapping Test for working memory;and the Trail Making Test A \& B and the Symbol Digit Modalities Test for attention. Classification will be obtained adopting the criteria proposed by the International Cognition and Cancer Task Force,a test score of 2 SDs or more below the test-specific reference cohort on at least 1 test of a cognitive domain.All test scores were transformed into z-scores to allow the comparison between different measures.

Secondary Outcomes

  • Risk factors on the cognitive profile of lung cancer patients(From baseline to 12 months)

Study Sites (1)

Loading locations...

Similar Trials